Fig 1.
Flow diagram for selection of randomized controlled trials (RCTs) included in the meta-analysis.
Table 1.
Characteristics of randomized controlled studies comparing oral beclomethasone dipropionate to oral aminosalicylates.
Fig 2.
This risk of bias tool incorporates the assessment of randomization (sequence generation and allocation concealment), blinding (participants and outcome assessors), incomplete outcome data, selective outcome reporting and other risk of bias. The items were judged as ‘low risk’ ‘unclear risk’ or ‘high risk’. Green means ‘low risk’ and red means ‘high risk’.
Table 2.
Data for the efficacy and safety analysis.
Fig 3.
Forest plot of randomized controlled trials of oral BDP vs. oral PD or 5-ASA in inducing clinical response in ulcerative colitis.
BDP, beclomethasone dipropionate. PD, prednisone. 5-ASA, mesalazine. M-H, Mantel-Haenszel.
Fig 4.
Forest plot of randomized controlled trials of oral BDP vs. oral PD or 5-ASA in inducing clinical remission in ulcerative colitis.
BDP, beclomethasone dipropionate. PD, prednisone. 5-ASA, mesalazine. M-H, Mantel-Haenszel.
Fig 5.
Forest plot of randomized controlled trials of oral BDP vs. oral PD or 5-ASA on adverse events appearance in ulcerative colitis.
BDP, beclomethasone dipropionate. PD, prednisone. 5-ASA, mesalazine. M-H, Mantel-Haenszel.
Fig 6.
Forest plot of randomized controlled trials of oral BDP vs. oral 5-ASA in inducing clinical response in ulcerative colitis.
BDP, beclomethasone dipropionate. 5-ASA, mesalazine. M-H, Mantel-Haenszel.
Fig 7.
Forest plot of randomized controlled trials of oral BDP vs. oral 5-ASA in inducing clinical remission in ulcerative colitis.
BDP, beclomethasone dipropionate. 5-ASA, mesalazine. M-H, Mantel-Haenszel.
Fig 8.
Forest plot of randomized controlled trials of oral BDP vs. oral 5-ASA on adverse events appearance in ulcerative colitis.
BDP, beclomethasone dipropionate. 5-ASA, mesalazine. M-H, Mantel-Haenszel.